NasdaqGM - Delayed Quote • USD
Vanda Pharmaceuticals Inc. (VNDA)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:30 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 0.05 | 0.02 | -0.06 | -0.33 |
| Low Estimate | 0.05 | 0.02 | -0.06 | -0.33 |
| High Estimate | 0.05 | 0.02 | -0.06 | -0.33 |
| Year Ago EPS | 0.12 | 0.03 | 0.04 | -0.06 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 48.5M | 47.5M | 194.5M | 232.4M |
| Low Estimate | 48.5M | 47.5M | 194.5M | 232.4M |
| High Estimate | 48.5M | 47.5M | 194.5M | 232.4M |
| Year Ago Sales | -- | 46.06M | 192.64M | 194.5M |
| Sales Growth (year/est) | -- | 3.10% | 1.00% | 19.50% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.08 | -0.13 | -0.04 | -0.09 |
| EPS Actual | 0.12 | 0.03 | 0 | -0.04 |
| Difference | 0.04 | 0.16 | 0.04 | 0.05 |
| Surprise % | 50.00% | 123.10% | 100.00% | 55.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.05 | 0.02 | -0.06 | -0.33 |
| 7 Days Ago | 0.05 | 0.02 | -0.06 | -0.33 |
| 30 Days Ago | 0.05 | 0.02 | 0.01 | -0.48 |
| 60 Days Ago | 0.05 | 0.02 | 0.01 | -0.48 |
| 90 Days Ago | -0.08 | -0.11 | -0.46 | -0.94 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | VNDA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -58.30% | -- | -- | 1.60% |
| Next Qtr. | -33.30% | -- | -- | 10.50% |
| Current Year | -250.00% | -- | -- | 5.20% |
| Next Year | -450.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 36.10% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -17.19% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | Jefferies: Buy to Hold | 2/25/2022 |
| Initiated | B of A Securities: Buy | 5/12/2021 |
| Downgrade | Citigroup: Buy to Neutral | 1/14/2021 |
| Upgrade | Citigroup: Neutral to Buy | 10/29/2020 |
| Downgrade | Citigroup: Buy to Neutral | 6/9/2020 |
| Upgrade | Citigroup: Neutral to Buy | 3/12/2020 |
Related Tickers
PALI Palisade Bio, Inc.
4.7100
-7.10%
LGVN Longeveron Inc.
1.9200
-4.48%
RLYB Rallybio Corporation
1.7600
+5.39%
ALLR Allarity Therapeutics, Inc.
1.3900
-9.74%
PXMD PaxMedica, Inc.
0.7609
-0.29%
ELYM Eliem Therapeutics, Inc.
3.8500
-7.89%
CADL Candel Therapeutics, Inc.
5.17
-5.31%
SNGX Soligenix, Inc.
0.4310
-0.99%
ADIL Adial Pharmaceuticals, Inc.
1.9300
-11.06%
ONVO Organovo Holdings, Inc.
1.1000
-4.35%